SIHUAN PHARM(00460) expects to achieve revenue of at least 2.5 billion yuan in 2025, with a growth rate of over 30% compared to the same period last year.

SIHUAN PHARM (00460) announced that, according to the initial assessment of the unaudited comprehensive management accounts as of December 31, 2025 and the existing information of the Board of Directors, the group expects to achieve revenue of not less than RMB 2.5 billion (an increase of over 30% compared to the same period last year) and a net profit of not less than RMB 150 million for the year. The main factors affecting the financial performance of the group during the year include: (1) The medical beauty business achieved rapid growth, with revenue exceeding RMB 1.4 billion and branch profit exceeding RMB 700 million for the year, both of which increased by over 90% compared to the previous year, becoming the largest revenue and profit pillar of the group, significantly boosting overall performance; (2) The innovative pharmaceutical business entered a harvest period, with substantial growth in revenue for Xuanzhu Biotechnology and Huisheng Biotechnology compared to the same period last year, optimization of research and development expenses for innovative drugs, continued emergence of newly approved products, smooth commercialization progress for new products, transition of the sector from investment to profit, and significant improvement in the group's profit structure; and (3) The company's financial position is sound, with sufficient cash on hand. Multiple rounds of share repurchases were implemented during the year and Xuanzhu Biotechnology was successfully listed, bringing significant equity appreciation benefits, not only alleviating research and development funding pressures but also optimizing the group's financial structure and driving a breakthrough in profitability. 2025 is a key turning point for the performance of SIHUAN PHARM. During the year, the group launched multiple new medical beauty and pharmaceutical products, which significantly improved the business structure and market competitiveness. In terms of the medical beauty sector, the group successfully obtained approval for several self-developed core products, including self-developed youth injections, self-developed girl injections, and other products. With the successive launch of multiple self-developed regenerative and hyaluronic acid products, SIHUAN PHARM has become the first medical beauty enterprise in the industry to offer a full range of products including botulinum toxin, youth injections, hyaluronic acid, photoelectric equipment, etc. The market share of the core product Lopibotulinum toxin has increased to nearly 20%, and the number of cooperating medical beauty institutions has exceeded 8000. With the influx of mature channels and core brand traffic, the company's newly launched medical beauty products have quickly gained traction, obtained high recognition from medical beauty institutions, and become an important driver of performance growth. Furthermore, the company is accelerating its global expansion and has formally signed an investment agreement with the Swiss medical beauty company Suisselle. Leveraging its sales network covering 43 countries, the company is pushing its self-developed medical beauty products into the EU market, forming a preliminary closed-loop layout in the European and American markets, laying a solid foundation for long-term sustainable growth. Looking ahead, SIHUAN PHARM will fully leverage the advantages of its medical beauty product portfolio, build an efficient service system with advisory-style marketing at its core and multi-dimensional products as carriers on the sales side, upgrade from a medical beauty product distributor to a professional medical beauty solutions provider, and establish a solid foundation for long-term stable growth in performance. The pharmaceutical business has made rapid progress in research and development, with Xuanzhu Biotechnology and Huisheng Biotechnology realizing a series of achievements. Xuanzhu Biotechnology's ALK inhibitor Xuanfening and CDK4/6 inhibitor Xuanyuing were successively approved for listing during the year, with Xuanyuing being included in the national medical insurance catalog and NG-350A receiving fast track qualification from the US FDA. Huisheng Biotechnology's semaglutide injection for lowering blood sugar has been accepted for new drug application, and its weight loss indication has completed Phase III clinical trials. Particularly important is the successful listing of Xuanzhu Biotechnology on the main board of the Hong Kong Stock Exchange in October 2025. This not only brought significant equity appreciation benefits to SIHUAN PHARM but also relieved the pressure on research and development investment through capital market financing, helping the company focus its resources on developing high-growth sectors such as medical beauty, providing important support for significant performance improvement and financial risk mitigation, and pushing the company into a new stage of high-quality development.